{"id":"NCT03452943","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-02-05","primaryCompletion":"2019-11-12","completion":"2019-11-12","firstPosted":"2018-03-02","resultsPosted":"2020-06-04","lastUpdate":"2021-11-09"},"enrollment":119,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tourette Syndrome"],"interventions":[{"type":"DRUG","name":"TEV-50717","otherNames":["Deutetrabenazine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TEV-50717","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.","primaryOutcome":{"measure":"Change From Baseline in the TTS of the YGTSS at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"TEV-50717","deltaMin":-9.1,"sd":1.28},{"arm":"Placebo","deltaMin":-8.4,"sd":1.25}],"pValues":[{"comp":"OG000 vs OG001","p":"0.692"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":42,"countries":["United States","Canada","Denmark","Russia","Serbia","Spain"]},"refs":{"pmids":["34609495"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Headache","Fatigue","Nausea","Weight increased","Upper respiratory tract infection"]}}